Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

被引:5
|
作者
Ando, Yukio [1 ]
Waddington-Cruz, Marcia [2 ]
Sekijima, Yoshiki [3 ]
Koike, Haruki [4 ,5 ]
Ueda, Mitsuharu [6 ]
Konishi, Hiroaki [7 ]
Ishii, Tomonori [7 ]
Coelho, Teresa [8 ]
机构
[1] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Amyloidosis Res, 2825-7 Huis Ten Bosch Sasebo, Sasebo, Nagasaki 8593298, Japan
[2] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Estudos Paramiloidose Antonio Rodrigues Mello, Rio De Janeiro, RJ, Brazil
[3] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Japan
[4] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Japan
[5] Saga Univ, Fac Med, Dept Internal Med, Div Neurol, Saga, Japan
[6] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[7] Pfizer Japan Inc, Tokyo, Japan
[8] Ctr Hosp Univ Porto, Hosp Santo Antonio, Andrades Ctr Familial Amyloidosis, Porto, Portugal
关键词
Asymptomatic; ATTR amyloidosis; Biopsy; Cardiomyopathy; Gene mutation carrier; Genetic counseling; Neuropathy; Noninvasive testing; Practical guidance; Predictive genetic testing; CARPAL-TUNNEL-SYNDROME; DIAGNOSTIC-ACCURACY; POLYNEUROPATHY; SYMPTOM; ONSET; PROGRESSION; PREVALENCE; TAFAMIDIS; CONSENSUS; FOCUS;
D O I
10.1186/s13023-023-02910-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients' genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients' nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
    Yukio Ando
    Marcia Waddington-Cruz
    Yoshiki Sekijima
    Haruki Koike
    Mitsuharu Ueda
    Hiroaki Konishi
    Tomonori Ishii
    Teresa Coelho
    Orphanet Journal of Rare Diseases, 18
  • [2] Real-world tafamidis experience in hereditary transthyretin amyloidosis with peripheral neuropathy in Brazil
    Pinto, Luiz Felipe
    Pinto, Marcus, V
    Accioli, Paula
    Amorim, Gabriela
    Rosa, Renata Gervais de Santa
    Dias, Moises
    Guedes, Mariana
    Gomez, Carlos P.
    Pedrosa, Roberto C.
    Waddington-Cruz, Marcia
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2025, 83 (01) : 13 - 13
  • [3] Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience
    Delstanche, Stephanie
    Claeys, Kristl G.
    De Bleecke, Gauthier
    Remiche, Gauthier
    Troisfontaines, Pierre
    Van Parys, Vinciane
    Bondue, Antoine
    ACTA CLINICA BELGICA, 2024, 79 (06) : 393 - 402
  • [4] Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
    Gentile, Luca
    Mazzeo, Anna
    Briani, Chiara
    Casagrande, Silvia
    De Luca, Marcella
    Fabrizi, Gian Maria
    Gagliardi, Christian
    Gemelli, Chiara
    Forcina, Francesca
    Grandis, Marina
    Guglielmino, Valeria
    Iabichella, Giacomo
    Leonardi, Luca
    Lozza, Alessandro
    Manganelli, Fiore
    Mussinelli, Roberta
    My, Filomena
    Occhipinti, Giuseppe
    Fenu, Silvia
    Russo, Massimo
    Romano, Angela
    Salvalaggio, Alessandro
    Tagliapietra, Matteo
    Tozza, Stefano
    Palladini, Giovanni
    Obici, Laura
    Luigetti, Marco
    NEUROLOGICAL SCIENCES, 2024, 45 (09) : 4563 - 4571
  • [5] Real-world data on hereditary amyloid transthyretin amyloidosis: Findings from a genetic testing program
    Khella, Sami
    Bumma, Naresh
    Gabriel, Aaron
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 568 - 568
  • [6] Tafamidis real-world effectiveness in hereditary transthyretin amyloidosis with polyneuropathy: A meta-analytic proof of concept
    Serrano, Daniel
    Atzinger, Christopher
    Botteman, Marc
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 289 - 290
  • [7] A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy
    Calabria, Silvia
    Ronconi, Giulia
    Dondi, Letizia
    Dondi, Leonardo
    Dell'Anno, Irene
    Piccinni, Carlo
    Esposito, Immacolata
    Addesi, Alice
    Gnesi, Marco
    Cosentino, Nicola
    D'Amelio, Marco
    Martini, Nello
    Maggioni, Aldo Pietro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [8] TAFAMIDIS FOR TREATMENT OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS: A REAL WORLD EXPERIENCE
    Vagnarelli, F.
    Brugiatelli, L.
    Lofiego, C.
    Capodaglio, I
    Patani, F.
    Tofoni, P.
    Maurizi, K.
    Pietrucci, F.
    Romandini, A.
    Contadini, D.
    Lanari, A.
    Bianco, M.
    Terzi, F.
    Paci, M.
    Olivieri, R.
    Flori, M.
    Dello Russo, A.
    Perna, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26 : ii4 - ii4
  • [9] Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany
    Morbach, Caroline
    Papagianni, Aikaterini
    Ihne-Schubert, Sandra
    Cejka, Vladimir
    Steinhardt, Maximilian
    Fette, Georg
    Held, Melissa
    Geier, Andreas
    Einsele, Hermann
    Frantz, Stefan
    Knop, Stefan
    Sommer, Claudia
    Stoerk, Stefan
    CLINICAL RESEARCH IN CARDIOLOGY, 2024, 113 (05) : 653 - 655
  • [10] Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany
    Caroline Morbach
    Aikaterini Papagianni
    Sandra Ihne-Schubert
    Vladimir Cejka
    Maximilian Steinhardt
    Georg Fette
    Melissa Held
    Andreas Geier
    Hermann Einsele
    Stefan Frantz
    Stefan Knop
    Claudia Sommer
    Stefan Störk
    Clinical Research in Cardiology, 2024, 113 : 653 - 655